Search

Roche NT-proBNP

The gold standard biomarker in heart failure

Elecsys® NT-proBNP
Improved heart failure management is key to better patient outcomes and quality of life.1-3
Heart failure (HF) management can be challenging.2,4,5 Roche NT-proBNP is a well-established HF biomarker that can accurately provide objective information to support clinical decision making from diagnosis to monitoring.4,6,7,9-24 NT-proBNP is recognised as the gold standard HF biomarker because it is a powerful prognosticator and has analytical advantages over BNP, especially in settings where patients are treated with a medication that inhibits the degradation of natriuretic peptides.22,23,27
Do you have any questions?
Contact Us

 

Roche NT-proBNP can help support your clinical decisions at every stage of patient care.4,6-26

 

As supported by recent international heart failure guidelines.4,6,7

Diagnosis

Diagnosis

 

As an initial test for diagnosis before echocardiography, Roche NT-proBNP is clinically validated to:

  • Support HF diagnosis procedure in both non-acute and acute settings1,4,6,7

  • Improve the specificity and accuracy of HF diagnosis, as the only biomarker with validated age-specific cutoffs10,14

In-hospital management

In-hospital management

Roche NT-proBNP can aid patient discharge planning. Pre-discharge absolute value of, and relative changes in, Roche NT-proBNP during hospitalisation can:

  • Provide valuable prognostic information17-19
  • Help identify patients at risk of hospital readmission or death in the following 6 months17-19
Disease monitoring

Disease monitoring

Roche NT-proBNP is a powerful prognosticator of patient outcomes, and is superior to BNP as a biomarker in patients treated with an angiotensin receptor-neprilysin inhibitor (ARNi).7,20-27

Monitoring NT-proBNP levels over time can provide insight into patients' disease progression.6,7,20,22,27

Assay specifications28

  • Assay time

    9 minute STAT assay, 18 minute assay

  • Sample material

    Li-heparin, K2-EDTA and K3-EDTA plasma

     

     

     

  • Sample volume

    15 μL

     

  • Measuring range

    5 - 35,000 ng/L

  • Sample stability

    Stable for 3 days at 20-25 °C, 6 days at 2-8 °C, 24 months at -20 °C (± 5 °C). Freeze only once.

Abbreviations

NT-proBNP: N-terminal prohormone of brain natriuretic peptide

 

References

 

  1. World Heart Failure Alliance: https://www.escardio.org/static_file/Escardio/Subspecialty/HFA/WHFA-whitepa-per-15-May-14.pdf. [Accessed January 2018, 23rd]
  2. Emdin, M., et al. (2008). Clin Chem Lab Med. 46, 1533-1542
  3. Lindenfeld et al. (2010). J Card Fail. 16, e1-e194
  4. Rutten et al. https://ipccs.org/2017/12/10/epccs-practical-guidance-on-heart-failurediagnosis-and-management-in-primary-care/ [Accessed on January 2018, 23rd]
  5. Krupicka et al. (2013). Cor et vasa. 55, e370-e376
  6. Ponikowski et al. (2016). Eur J Heart Fail. 18, 891-975
  7. Yancy et al. (2017). Circulation. 136, e137-e161
  8. PubMed Central®: search results for “Roche NT-proBNP heart failure”. [Accessed on January 2018, 23rd]
  9. Taylor et al. (2017). Br J Gen Pract. 67, e94-e102
  10. Januzzi et al. (2018). J Am Coll Cardiol 71, 1191-1200
  11. Taylor et al. (2017). Efficacy and Mechanism Evaluation, No. 4.3. National Institute for Health Research. ISSN 2050-4365. [Accessed on January 2018, 23rd]
  12. British Heart Foundation and the All-Party Parliamentary Group on Heart Disease: https://www.bhf.org.uk/get-involved/campaigning/inquiry-into-living-with-heart-failure [Accessed on January 2018, 23rd]
  13. Hildebrandt et al. (2010). Eur Heart J. 31, 1881-1889
  14. Januzzi et al. (2006). Eur Heart J. 27, 330-337
  15. Moe et al. (2007). Circulation. 115, 3103-3110
  16. Behnes et al. (2009). Int J Cardiol. 135, 165-174
  17. Bettencourt (2004). Circulation. 110, 2168-2174
  18. Salah et al. (2014). Heart. 100, 115-125
  19. Stienen et al. (2015) Eur J Heart Fail. 17, 936-944
  20. Masson et al. (2008). J Am Coll Cardiol. 52, 997-100
  21. Januzzi (2012). Arch Cardiovasc Dis. 105, 40-50
  22. Zile et al (2016). J Am Coll Cardiol. 68, 2425-2436
  23. Deberadinis and Januzzi. (2012). Curr Opin Cardiol. 27, 66-668
  24. Chiong et al. (2010). Heart Fail Rev. 15, 275-291
  25. Weiner et al. (2012). Eur J Heart Fail. 15, 342-351
  26. Gaggin et al. (2013). Congest Heart Fail. 19, 135-42
  27. McKie and Burnett (2016). J Am Coll Cardiol. 62, 2437-2439
  28. Roche Diagnostics Ltd. Roche NT-proBNP package insert